JULUCA Drug Patent Profile

When do Juluca patents expire, and what generic alternatives are available?

Juluca is a drug marketed by Viiv Hlthcare and is included in one NDA. There are four patents protecting this drug and one Paragraph IV challenge.

This drug has three hundred and twenty-two patent family members in fifty-one countries.

The generic ingredient in JULUCA is dolutegravir sodium; rilpivirine hydrochloride. There are seventeen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the dolutegravir sodium; rilpivirine hydrochloride profile page.

DrugPatentWatch^® Generic Entry Outlook for Juluca

Juluca was eligible for patent challenges on August 12, 2017.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be September 5, 2038. This may change due to patent challenges or generic licensing.

There have been twenty-seven patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for JULUCA

International Patents:	322
US Patents:	4
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for JULUCA

Paragraph IV (Patent) Challenges for JULUCA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
JULUCA	Tablets	dolutegravir sodium; rilpivirine hydrochloride	50 mg/25 mg	210192	1	2019-11-19

US Patents and Regulatory Information for JULUCA

JULUCA is protected by four US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Viiv Hlthcare	JULUCA	dolutegravir sodium; rilpivirine hydrochloride	TABLET;ORAL	210192-001	Nov 21, 2017		RX	Yes	Yes			Y	Y
Viiv Hlthcare	JULUCA	dolutegravir sodium; rilpivirine hydrochloride	TABLET;ORAL	210192-001	Nov 21, 2017		RX	Yes	Yes					Y
Viiv Hlthcare	JULUCA	dolutegravir sodium; rilpivirine hydrochloride	TABLET;ORAL	210192-001	Nov 21, 2017		RX	Yes	Yes			Y
Viiv Hlthcare	JULUCA	dolutegravir sodium; rilpivirine hydrochloride	TABLET;ORAL	210192-001	Nov 21, 2017		RX	Yes	Yes					Y

International Patents for JULUCA

When does loss-of-exclusivity occur for JULUCA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

European Patent Office

Israel

Japan

Mexico

Russian Federation

South Korea

Taiwan

United Kingdom

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering JULUCA around the world.

Country	Patent Number	Title	Estimated Expiration
Poland	1663240
European Patent Office	3127542
South Korea	20130133061	POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY
Japan	2008540343

Supplementary Protection Certificates for JULUCA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1632232	CA 2016 00065	Denmark		PRODUCT NAME: EN KOMBINATION AF: RILPIVIRINHYDROCHLORID ELLER EN TERAPEUTISK AEKVIVALENT FORM DERAF SOM ER BESKYTTET AF GRUNDPATENTET, OG TENOFOVIRALAFENAMID, ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, SAERLIGT TENOFOVIRALAFENAMIDFUMARAT; REG. NO/DATE: EU/1/16/1112/001 20160623
2465580	768	Finland
3808743	2022C/531	Belgium		PRODUCT NAME: EEN COMBINATIE VAN RILPIVIRINE OF EEN FARMACEUTISCH AANVAARDBAAR ADDITIEZOUT VAN RILPIVIRINE, EN EMTRICITABINE; AUTHORISATION NUMBER AND DATE: EU/1/11/737/001-002 20111128
3808743	122022000051	Germany		PRODUCT NAME: KOMBINATION VON RILPIVIRIN ODER EINER THERAPEUTISCH AEQUIVALENTEN FORM DAVON, DIE DURCH DAS GRUNDPATENT GESCHUETZT IST, WIE EIN PHARMAZEUTISCH AKZEPTABLES ADDITIONSSALZ VON RILPIVIRIN, EINSCHLIESSLICH DES SALZSAEURESALZES VON RILPIVIRIN, UND EMTRICITABIN.; REGISTRATION NO/DATE: EU/1/11/737/001-002 20111128

JULUCA (Trilostane) Pharmaceutical Investment Analysis

Last updated: February 19, 2026

JULUCA, a trilostane-based treatment for Cushing's disease in dogs, presents a specific investment profile within the veterinary pharmaceutical market. Marketed by Elanco Animal Health, JULUCA addresses a chronic condition with limited alternative treatment options, positioning it for sustained revenue generation. The drug's mechanism of action and clinical efficacy are established, but patent exclusivity and market penetration strategies will dictate future growth.

What is the Market Opportunity for JULUCA?

The global veterinary pharmaceutical market is projected to reach $60 billion by 2025, driven by increasing pet ownership and a willingness among owners to invest in animal health. Cushing's disease, also known as hyperadrenocorticism, is a prevalent endocrine disorder in dogs, affecting an estimated 1.6% of the canine population. This translates to a significant addressable market for effective treatments.

• Prevalence of Cushing's Disease: Studies indicate that between 0.5% and 1.6% of dogs are diagnosed with Cushing's disease annually [1].
• Age Demographics: The disease predominantly affects middle-aged to older dogs, with the average age of diagnosis being seven years [2].
• Breed Predisposition: Certain breeds, including Poodles, Dachshunds, and German Shepherds, exhibit a higher incidence of the disease [2].
• Treatment Costs: The chronic nature of Cushing's disease necessitates long-term management, including medication, diagnostic testing, and veterinary consultations, contributing to substantial owner expenditure on affected pets.

Elanco's JULUCA offers a once-daily oral formulation of trilostane, designed to inhibit cortisol production by the adrenal glands. This simplifies the treatment regimen compared to historically available compounded or less stable formulations, potentially improving owner compliance and therapeutic outcomes.

What is the Patent Landscape for Trilostane and JULUCA?

The patent landscape surrounding trilostane is complex, with core patents for the active pharmaceutical ingredient (API) having expired. Elanco's intellectual property for JULUCA primarily centers on specific formulations, manufacturing processes, and potentially new therapeutic uses or delivery methods.

• Core Trilostane Patents: The fundamental patents for trilostane as a therapeutic agent have expired. For example, U.S. Patent 3,598,847 for trilostane was granted in 1971 and expired decades ago.
• Elanco's JULUCA Patents: Elanco holds patents related to the specific composition and manufacturing of JULUCA. These patents aim to protect the drug product from generic competition by providing exclusivity for its unique formulation and delivery system.
  • Example Patent: U.S. Patent 8,889,717, titled "Trilostane Formulations," was granted to Elanco in 2014 and is scheduled to expire in 2031. This patent covers specific pharmaceutical compositions containing trilostane, providing a period of market exclusivity.
  • Other Related Patents: Elanco may hold additional patents covering specific manufacturing processes, synergistic combinations, or veterinary uses of trilostane that extend their protection. A comprehensive review of the USPTO and WIPO databases is necessary for a complete picture.
• Generic Competition: With the expiration of core trilostane patents, the primary risk for Elanco lies in potential generic competition for trilostane formulations once JULUCA's formulation patents expire. This competition could lead to price erosion and a reduction in market share.

The duration of JULUCA's patent protection is critical for its long-term revenue potential. While the API is off-patent, the specific formulation patents provide a window of market exclusivity that Elanco can leverage.

What is the Competitive Environment for JULUCA?

The primary competition for JULUCA includes other trilostane formulations (both branded and compounded) and alternative treatment modalities for Cushing's disease.

• Other Trilostane Products:
  • Vetoryl (Dechra Pharmaceuticals): This is Elanco's most direct competitor, also containing trilostane. Vetoryl has been a long-standing treatment option.
  • Compounded Trilostane: Veterinarians can prescribe compounded trilostane formulations from specialized pharmacies. These can be less standardized in terms of API purity, potency, and stability compared to FDA-approved products like JULUCA and Vetoryl, posing a risk of inconsistent therapeutic outcomes.
• Alternative Treatments:
  • Lysodren (Mitotane): This is an older treatment for Cushing's disease that works by destroying adrenal tissue. It is often used for more severe cases and requires careful monitoring due to its toxicity profile.
  • Surgery: In specific cases, surgical removal of adrenal tumors can be an option, but it is invasive and carries significant risks.
  • Medical Management of Symptoms: Some treatments focus on managing the clinical signs of Cushing's disease rather than addressing the underlying hormonal imbalance.

JULUCA's market position is strengthened by its once-daily dosing and established efficacy. Elanco's marketing efforts will focus on differentiating JULUCA from Vetoryl and discouraging the use of compounded alternatives by emphasizing its quality, consistency, and veterinary-approved status.

What is the Financial Performance and Outlook for JULUCA?

Elanco's financial reporting typically segments its revenue by therapeutic area or product category. Specific revenue figures for JULUCA are not always broken out individually but are often included within broader "Companion Animal" or "Endocrine" categories.

• Revenue Contribution: While precise figures are proprietary, JULUCA is a significant contributor to Elanco's companion animal portfolio. The market for endocrine treatments in companion animals is substantial.
• Growth Drivers:
  • Increased Diagnosis Rates: Enhanced veterinary diagnostic capabilities and owner awareness are likely to drive an increase in Cushing's disease diagnoses, expanding the patient pool for JULUCA.
  • Owner Compliance: The once-daily dosing of JULUCA improves owner compliance compared to more complex regimens, leading to better treatment adherence and potentially higher demand.
  • Market Penetration: Elanco's sales and marketing efforts aim to capture market share from competitors and expand the overall use of trilostane-based therapies.
• Future Projections: Based on market trends and the drug's established position, JULUCA is expected to maintain steady revenue growth. However, the eventual expiration of its formulation patents will introduce a critical inflection point, potentially leading to increased generic competition and price pressure. Elanco's strategy will likely involve lifecycle management, including exploring new indications or formulations to extend market exclusivity.

What are the Key Risks and Opportunities for JULUCA?

Risks:

• Generic Competition: The expiration of formulation patents will open the door for generic trilostane products, leading to price erosion and reduced market share.
• Regulatory Scrutiny: Any adverse events or post-market safety concerns could lead to regulatory action, impacting sales and reputation.
• Pricing Pressures: Competition from both branded and potentially lower-cost generic alternatives could lead to pricing pressures.
• Market Access and Formulary Inclusion: Continued access to veterinary formularies and effective reimbursement strategies are crucial.

Opportunities:

• Market Growth: The expanding pet population and increasing owner willingness to spend on veterinary care provide a solid foundation for continued market growth.
• Improved Formulations: Elanco's focus on developing and patenting improved formulations of trilostane could extend market exclusivity and provide a competitive advantage.
• Broader Indications: Exploration and approval for new indications or use in different animal species could expand the addressable market.
• Combination Therapies: Research into synergistic effects with other veterinary drugs could lead to new treatment protocols.

Key Takeaways

JULUCA (trilostane) is a well-established veterinary pharmaceutical product for Cushing's disease in dogs, operating within a growing market. Elanco Animal Health holds formulation patents that currently provide market exclusivity, with key patents expiring in the mid-2030s. The competitive landscape includes other trilostane products like Vetoryl and compounded alternatives. Risks include the eventual impact of generic competition and potential regulatory issues. Opportunities lie in market growth, potential for improved formulations, and expanded indications.

FAQs

1. What is the primary mechanism of action for trilostane in treating Cushing's disease? Trilostane inhibits the enzyme 3-beta-hydroxysteroid dehydrogenase in the adrenal glands, thereby blocking the synthesis of cortisol.

2. When do the key formulation patents for JULUCA expire? Key formulation patents, such as U.S. Patent 8,889,717, are scheduled to expire around 2031.

3. What are the main competitors to JULUCA in the veterinary market? The primary branded competitor is Vetoryl (dechra Pharmaceuticals). Compounded trilostane formulations also represent a segment of competition.

4. What are the typical breed predispositions for Cushing's disease in dogs? Breeds such as Poodles, Dachshunds, German Shepherds, and Beagles are known to have a higher incidence of Cushing's disease.

5. Does Elanco Animal Health have any plans for lifecycle management of JULUCA? While specific future plans are proprietary, pharmaceutical companies typically pursue lifecycle management through developing new formulations, exploring new indications, or seeking patent extensions for manufacturing processes.

Citations

[1] Beaver, B. V. (2010). Canine hyperadrenocorticism. Veterinary Clinics of North America: Small Animal Practice, 40(2), 217–234.

[2] Meijer, B. L., & van den Brom, W. E. (2007). Treatment of Cushing's disease in dogs. The Veterinary Journal, 174(3), 467–473.